An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

NCT01739764 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Vemurafenib

Sponsor

Hoffmann-La Roche